Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update DALLAS, TX, May 10, 2024 (GLOBE NEWSWIRE) - Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update. Recent Highlights: • With successful completion of feasibility studies, preparations are underway with collaborator for a potential investigator-initiated ...